secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-124542
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee Therapeutics Reports Q3 2024 Financial Results and Pipeline Progress
---------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities of $753.8M as of Sept 30, 2024, with runway into 2028.
- Net loss for Q3 2024 was $49.0M, compared to $20.8M in Q3 2023.
- APG777 Phase 2 Part A data expected in 2H 2025; interim Phase 1 data for APG808 in 4Q 2024.
- APG333 development candidate nominated; Phase 1 planned for late 2024 or early 2025.
- Jeff S. Hartness appointed as Chief Commercial Officer in September 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000095017024124542/0000950170-24-124542-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000095017024124542/apge-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-124542

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer